Works matching Hydralazine


Results: 1029
    1

    Mini review: The clinical avenues of combined hydralazine-nitrate in subjects with heart failure with reduced ejection fraction.

    Published in:
    Pharmacy Practice (1886-3655), 2023, v. 21, n. 2, p. 1, doi. 10.18549/PharmPract.2023.2.2824
    By:
    • Elnour, Asim Ahmed;
    • Sadeq, Adel;
    • Ramadan, Azza;
    • AlAmoodi, Abdulla;
    • Alkwarit, Alin;
    • Alshammari, Asma Faisal;
    • EL Khidir, Israa Yousif;
    • Alrashidi, Nouf Eid;
    • kouhgard, Parisa;
    • Qahtani, Mariam Mohamed Al;
    • Beshir, Semira Abdi;
    • Al-Kubaisi, Khalid Awad;
    • Al Mazrouei, Nadia;
    • Alkaabi, Maisoun;
    • Ashoor, Afaf
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Hydralazine-induced pericardial effusion.

    Published in:
    Baylor University Medical Center Proceedings, 2019, v. 32, n. 3, p. 377, doi. 10.1080/08998280.2019.1613331
    By:
    • Rahman, Mohammed Faisal;
    • Panezai, Muhammad Ajmal;
    • Szerlip, Harold M.
    Publication type:
    Article
    11
    12
    13
    14

    Antibacterial and Antibiofilm Activities of Hydralazine, an Antihypertensive Drug: In Vitro and In Silico Approaches.

    Published in:
    Antibiotics (2079-6382), 2025, v. 14, n. 3, p. 286, doi. 10.3390/antibiotics14030286
    By:
    • Pereira, Antônio Mateus Gomes;
    • da Silva, Benise Ferreira;
    • Araujo, Ingrid Maria Frota;
    • Aguiar, Francisco Kauê Carvalho;
    • Coelho, Paulo Adenes Teixeira;
    • Costa, Renata Albuquerque;
    • Marinho, Marcia Machado;
    • Marinho, Emmanuel Silva;
    • Nunes, João Victor Serra;
    • Carneiro, Victor Alves;
    • Santos, Hélcio Silva dos
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22

    Genotype-Guided Hydralazine Therapy.

    Published in:
    American Journal of Nephrology, 2020, v. 51, n. 10, p. 764, doi. 10.1159/000510433
    By:
    • Collins, Kimberly S.;
    • Raviele, Anthony L.J.;
    • Elchynski, Amanda L.;
    • Woodcock, Alexander M.;
    • Zhao, Yang;
    • Cooper-DeHoff, Rhonda M.;
    • Eadon, Michael T.
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.

    Published in:
    Annals of Hematology, 2011, v. 90, n. 4, p. 379, doi. 10.1007/s00277-010-1090-2
    By:
    • Candelaria, Myrna;
    • Herrera, Aquileo;
    • Labardini, Juan;
    • González-Fierro, Aurora;
    • Trejo-Becerril, Catalina;
    • Taja-Chayeb, Lucía;
    • Pérez-Cárdenas, Enrique;
    • de la Cruz-Hernández, Erick;
    • Arias-Bofill, Daymi;
    • Vidal, Silvia;
    • Cervera, Eduardo;
    • Dueñas-Gonzalez, Alfonso
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission.

    Published in:
    Cardiovascular Research, 2022, v. 118, n. 1, p. 282, doi. 10.1093/cvr/cvaa343
    By:
    • Kalkhoran, Siavash Beikoghli;
    • Kriston-Vizi, Janos;
    • Hernandez-Resendiz, Sauri;
    • Crespo-Avilan, Gustavo E;
    • Rosdah, Ayeshah A;
    • Lees, Jarmon G;
    • Costa, Joana Rodrigues Simoes Da;
    • Ling, Naomi X Y;
    • Holien, Jessica K;
    • Samangouei, Parisa;
    • Chinda, Kroekkiat;
    • Yap, En Ping;
    • Riquelme, Jaime A;
    • Ketteler, Robin;
    • Yellon, Derek M;
    • Lim, Shiang Y;
    • Hausenloy, Derek J
    Publication type:
    Article
    49
    50